Hansa Medical is a biopharmaceutical company focused on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. Our central asset, drug candidate imlifidase, is currently in late stage clinical development with potential in several indications.

We have an ongoing dialogue with potential collaboration partners regarding co-development and co-marketing opportunities for our current projects.

We continuously seek novel opportunities to broaden our development pipeline in scientific or therapeutic areas related to our current focus.

For more information about our business and how to partner with us, please contact our business development team at